Skip to main content
Premium Trial:

Request an Annual Quote

SDIX Q3 Revenues Slide 8 Percent

NEW YORK (GenomeWeb News) – SDIX reported after the close of the market on Monday that revenues for the third quarter dropped 8 percent year over year.

Total revenues for the three months ended Sept. 30 came in at $6.9 million, compared to $7.5 million, although Life Science revenues rose 11 percent to $4.1 million from $3.7 million a year ago. Food Safety revenues retreated to $1.5 million, down 6 percent from $1.6 million a year, while SDIX's Ag-GMO Products were down 43 percent to $400,000 from $700,000, and its Water & Environmental Products business fell 40 percent to $900,000 from $1.5 million.

R&D spending increased to $1.1 million from $767,000 a year ago as the company further developed its next-generation genomic Antibody Technology (GAT) platform. SG&A costs were flat at $3.7 million.

SDIX's net loss rose to $694,000, or $.03 per share, from $29,000, or break-even, from a year ago. In a statement, the company said the increase was due to lower revenues and increased costs related to the build-out of the GAT platform.

It finished the quarter with 7 million in cash and cash equivalents and $400,000 in restricted cash.

Filed under

The Scan

CDC Calls Delta "Variant of Concern"

CNN reports the US Centers for Disease Control and Prevention now considers the Delta variant of SARS-CoV-2 to be a "variant of concern."

From FDA to Venture Capital

Former FDA Commissioner Stephen Hahn is taking a position at a venture capital firm, leading some ethicists to raise eyebrows, according to the Washington Post.

Consent Questions

Nature News writes that there are questions whether informed consent was obtained for some submissions to a database of Y-chromosome profiles.

Cell Studies on Multimodal Single-Cell Analysis, Coronaviruses in Bats, Urban Microbiomes

In Cell this week: approach to analyze multimodal single-cell genomic data, analysis of bat coronaviruses, and more.